{"id":15589,"date":"2026-03-18T00:00:00","date_gmt":"2026-03-18T00:00:00","guid":{"rendered":"https:\/\/angelboss.com.br\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/"},"modified":"2026-03-18T00:00:00","modified_gmt":"2026-03-18T00:00:00","slug":"328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao","status":"publish","type":"post","link":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/","title":{"rendered":"Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o"},"content":{"rendered":"<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA Samsung Bioepis Co., Ltd. anunciou hoje que a empresa firmou um acordo global de licen\u00e7a, desenvolvimento e comercializa\u00e7\u00e3o (DCA) com a Sandoz para at\u00e9 cinco candidatos a biossimilares em desenvolvimento pela Samsung Bioepis, incluindo o SB36, um candidato a biossimilar que tem como refer\u00eancia o Entyvio<sup>1<\/sup> (vedolizumabe). Os demais termos do acordo permanecem confidenciais.<\/p>\n<p id=\"news-body-cta\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">Este comunicado de imprensa inclui multim\u00e9dia. Veja o comunicado completo aqui: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260318418361\/pt\/\" rel=\"follow\" target=\"_blank\">https:\/\/www.businesswire.com\/news\/home\/20260318418361\/pt\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260318418361\/pt\/2463563\/4\/Samsung_Bioepis_Songdo.jpg\" alt=\"Samsung Bioepis office in Songdo, Incheon, Republic of Korea\"><\/p>\n<p style=\"font-size:85%;\">Samsung Bioepis office in Songdo, Incheon, Republic of Korea<\/p>\n<\/div>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nSob os termos do acordo, a Samsung Bioepis ser\u00e1 respons\u00e1vel pelo desenvolvimento, registro regulat\u00f3rio nos principais mercados e fabrica\u00e7\u00e3o dos biossimilares, enquanto a Sandoz ser\u00e1 respons\u00e1vel pela comercializa\u00e7\u00e3o nos mercados globais, excluindo China, Hong Kong, Taiwan, Macau e Rep\u00fablica da Coreia.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n\u201cEstamos muito satisfeitos em expandir nossa parceria bem-sucedida com a Sandoz e em firmar um acordo de comercializa\u00e7\u00e3o para m\u00faltiplos ativos biossimilares que est\u00e3o em est\u00e1gio inicial de desenvolvimento. O acordo representa um avan\u00e7o significativo na melhoria do acesso a medicamentos biol\u00f3gicos para pacientes que vivem com condi\u00e7\u00f5es debilitantes e que t\u00eam acesso limitado a tratamentos que podem transformar suas vidas\u201d, disse Kyung-Ah Kim, presidente e CEO da Samsung Bioepis. \u201cNa Samsung Bioepis, continuaremos a demonstrar nosso compromisso cont\u00ednuo com os biossimilares, fortalecendo ainda mais nosso pipeline e ampliando sua disponibilidade para pacientes e sistemas de sa\u00fade em todas as partes do mundo.\u201d<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nSB36, em desenvolvimento pr\u00e9-cl\u00ednico na Samsung Bioepis, faz refer\u00eancia ao Entyvio (vedolizumabe), que \u00e9 indicado para o tratamento de pacientes adultos com doen\u00e7a de Crohn, colite ulcerativa e pouchite.<sup>2<\/sup><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO acordo amplia a parceria global entre as duas empresas para o PYZCHIVA<sup>\u00ae<\/sup> (ustecinumabe), estabelecida em setembro de 2023. O PYZCHIVA foi lan\u00e7ado pela primeira vez na Europa em julho de 2024 e nos Estados Unidos em fevereiro de 2025. Em dezembro de 2025, as empresas tamb\u00e9m assinaram um acordo para a comercializa\u00e7\u00e3o do EPYSQLI\u2122, um biossimilar do Soliris <sup>3<\/sup> (eculizumabe), para a regi\u00e3o do Oriente M\u00e9dio e da \u00c1frica.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b><span class=\"bwuline\">Sobre a Samsung Bioepis Co., Ltd.<\/span><\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nFundada em 2012, a Samsung Bioepis \u00e9 uma empresa biofarmac\u00eautica comprometida em tornar a sa\u00fade mais acess\u00edvel a todos. Por meio da inova\u00e7\u00e3o no desenvolvimento de produtos e de um s\u00f3lido compromisso com a qualidade, a Samsung Bioepis busca se consolidar como uma das principais empresas biofarmac\u00eauticas do mundo. Como subsidi\u00e1ria integral da Samsung Bioepis Holdings, a empresa continua a avan\u00e7ar com um amplo portf\u00f3lio de candidatos biol\u00f3gicos, abrangendo diversas \u00e1reas terap\u00eauticas, como imunologia, oncologia, oftalmologia, hematologia, nefrologia e endocrinologia. Para informa\u00e7\u00f5es adicionais, visite <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungbioepis.com&amp;esheet=54446523&amp;newsitemid=20260318418361&amp;lan=pt-BR&amp;anchor=www.samsungbioepis.com&amp;index=1&amp;md5=d1f43e4a8e90b4d14223d00c592017a2\" rel=\"follow\" shape=\"rect\" target=\"_blank\">www.samsungbioepis.com<\/a> e siga-nos no <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsamsungbioepis%2F&amp;esheet=54446523&amp;newsitemid=20260318418361&amp;lan=pt-BR&amp;anchor=LinkedIn&amp;index=2&amp;md5=9a4d8df7d9dcc813603d52407437b73d\" rel=\"follow\" shape=\"rect\" target=\"_blank\">LinkedIn<\/a> e no <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FSamsungBioepis%2F&amp;esheet=54446523&amp;newsitemid=20260318418361&amp;lan=pt-BR&amp;anchor=X&amp;index=3&amp;md5=7a4167b5aaa070e8b00777cc28c5b08d\" rel=\"follow\" shape=\"rect\" target=\"_blank\">X<\/a>.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwwidth32\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwwidth67\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth1 bwalignl bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>1<\/sup><\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignl bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nEntyvio \u00e9 uma marca registrada da Takeda Pharmaceuticals.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth1 bwalignl bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>2<\/sup><\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignl bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nEuropean Medicines Agency (EMA). Entyvio. Summary of Product Characteristics. Dispon\u00edvel em: <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Fentyvio-epar-product-information_en.pdf&amp;esheet=54446523&amp;newsitemid=20260318418361&amp;lan=pt-BR&amp;anchor=Entyvio%2C+%28DCI%3A+vedolizumabe%29&amp;index=4&amp;md5=550d69a2dddbe0439cc64984f408f84b\" rel=\"follow\" shape=\"rect\" target=\"_blank\">Entyvio, (DCI: vedolizumabe)<\/a>. \u00daltimo acesso em mar\u00e7o de 2026.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth1 bwalignl bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>3<\/sup><\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignl bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nSoliris \u00e9 uma marca registrada da Alexion Pharmaceuticals<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO texto no idioma original deste an\u00fancio \u00e9 a vers\u00e3o oficial autorizada. As tradu\u00e7\u00f5es s\u00e3o fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que \u00e9 a \u00fanica vers\u00e3o do texto que tem efeito legal.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260318418361r1&amp;sid=brdno&amp;distro=ftp\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><span id=\"mmgallerylink-phrase\">Ver a vers\u00e3o original em businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260318418361\/pt\/\" rel=\"follow\" target=\"_blank\">https:\/\/www.businesswire.com\/news\/home\/20260318418361\/pt\/<\/a><\/span><\/p>\n<p><b>Contato:<\/b><\/p>\n<p><b><span class=\"bwuline\">Assessoria de m\u00eddia<\/span><\/b><\/p>\n<p>Anna Nayun Kim, <a href=\"mailto:nayun86.kim@samsung.com\" rel=\"follow\" shape=\"rect\">nayun86.kim@samsung.com<br \/>\n<\/a><\/p>\n<p>Yoon Kim, <a href=\"mailto:yoon1.kim@samsung.com\" rel=\"follow\" shape=\"rect\">yoon1.kim@samsung.com<\/a><\/p>\n<p><strong>Fonte: <\/strong><a href='http:\/\/www.businesswire.com\/portal\/site\/home\/' target='_blank'>BUSINESS WIRE<\/a><img src='https:\/\/api.dino.com.br\/v2\/news\/tr\/328575?partnerId=4593' alt=\"\" style=\"border:0px;width:1px;height:1px;\" \/><\/p>","protected":false},"excerpt":{"rendered":"<p>O acordo abrange at\u00e9 cinco ativos, incluindo o SB36, um candidato a biossimilar baseado no Entyvio (vedolizumabe), para colabora\u00e7\u00e3o no desenvolvimento e comercializa\u00e7\u00e3o em mercados globais, excluindo China, Hong Kong, Taiwan, Macau e Rep\u00fablica da CoreiaA Samsung Bioepis continua abrindo caminho para o acesso a medicamentos que transformam vidas, promovendo um pipeline de biossimilares nas \u00e1reas de imunologia e oncologia\u00a0<\/p>","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[315],"tags":[349,324,352],"class_list":{"0":"post-15589","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-noticias-corporativas-dino","7":"tag-arte","8":"tag-negocios","9":"tag-saude-e-bem-estar"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss\" \/>\n<meta property=\"og:description\" content=\"O acordo abrange at\u00e9 cinco ativos, incluindo o SB36, um candidato a biossimilar baseado no Entyvio (vedolizumabe), para colabora\u00e7\u00e3o no desenvolvimento e comercializa\u00e7\u00e3o em mercados globais, excluindo China, Hong Kong, Taiwan, Macau e Rep\u00fablica da CoreiaA Samsung Bioepis continua abrindo caminho para o acesso a medicamentos que transformam vidas, promovendo um pipeline de biossimilares nas \u00e1reas de imunologia e oncologia\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/\" \/>\n<meta property=\"og:site_name\" content=\"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260318418361\/pt\/2463563\/4\/Samsung_Bioepis_Songdo.jpg\" \/>\n<meta name=\"author\" content=\"DINO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DINO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/\"},\"author\":{\"name\":\"DINO\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#\\\/schema\\\/person\\\/b6676b8d991f97199ef2d5b8e5c2d8a5\"},\"headline\":\"Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o\",\"datePublished\":\"2026-03-18T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/\"},\"wordCount\":591,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260318418361\\\/pt\\\/2463563\\\/4\\\/Samsung_Bioepis_Songdo.jpg\",\"keywords\":[\"ARTE\",\"NEG\u00d3CIOS\",\"SA\u00daDE E BEM-ESTAR\"],\"articleSection\":[\"Not\u00edcias Corporativas\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/\",\"url\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/\",\"name\":\"Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260318418361\\\/pt\\\/2463563\\\/4\\\/Samsung_Bioepis_Songdo.jpg\",\"datePublished\":\"2026-03-18T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260318418361\\\/pt\\\/2463563\\\/4\\\/Samsung_Bioepis_Songdo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260318418361\\\/pt\\\/2463563\\\/4\\\/Samsung_Bioepis_Songdo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/2026\\\/03\\\/18\\\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/angelboss.com.br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#website\",\"url\":\"https:\\\/\\\/angelboss.com.br\\\/\",\"name\":\"Portal Masculino de Moda, Beleza, Luxo e Business - Angel Boss\",\"description\":\"O Maior Portal sobre Moda, Luxo, Beleza e Business Masculino do Brasil\",\"publisher\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#organization\"},\"alternateName\":\"Maior Portal e Blog de Beleza Masculina e Luxo\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/angelboss.com.br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#organization\",\"name\":\"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss\",\"url\":\"https:\\\/\\\/angelboss.com.br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/angelboss.com.br\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/WhatsApp-Image-2025-12-11-at-12.54.26.jpeg\",\"contentUrl\":\"http:\\\/\\\/angelboss.com.br\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/WhatsApp-Image-2025-12-11-at-12.54.26.jpeg\",\"width\":1280,\"height\":1280,\"caption\":\"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss\"},\"image\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#\\\/schema\\\/person\\\/b6676b8d991f97199ef2d5b8e5c2d8a5\",\"name\":\"DINO\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g\",\"caption\":\"DINO\"},\"url\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/author\\\/DINO\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/","og_locale":"en_US","og_type":"article","og_title":"Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss","og_description":"O acordo abrange at\u00e9 cinco ativos, incluindo o SB36, um candidato a biossimilar baseado no Entyvio (vedolizumabe), para colabora\u00e7\u00e3o no desenvolvimento e comercializa\u00e7\u00e3o em mercados globais, excluindo China, Hong Kong, Taiwan, Macau e Rep\u00fablica da CoreiaA Samsung Bioepis continua abrindo caminho para o acesso a medicamentos que transformam vidas, promovendo um pipeline de biossimilares nas \u00e1reas de imunologia e oncologia\u00a0","og_url":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/","og_site_name":"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss","article_published_time":"2026-03-18T00:00:00+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260318418361\/pt\/2463563\/4\/Samsung_Bioepis_Songdo.jpg","type":"","width":"","height":""}],"author":"DINO","twitter_card":"summary_large_image","twitter_misc":{"Written by":"DINO","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/#article","isPartOf":{"@id":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/"},"author":{"name":"DINO","@id":"https:\/\/angelboss.com.br\/#\/schema\/person\/b6676b8d991f97199ef2d5b8e5c2d8a5"},"headline":"Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o","datePublished":"2026-03-18T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/"},"wordCount":591,"commentCount":0,"publisher":{"@id":"https:\/\/angelboss.com.br\/#organization"},"image":{"@id":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260318418361\/pt\/2463563\/4\/Samsung_Bioepis_Songdo.jpg","keywords":["ARTE","NEG\u00d3CIOS","SA\u00daDE E BEM-ESTAR"],"articleSection":["Not\u00edcias Corporativas"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/","url":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/","name":"Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss","isPartOf":{"@id":"https:\/\/angelboss.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/#primaryimage"},"image":{"@id":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260318418361\/pt\/2463563\/4\/Samsung_Bioepis_Songdo.jpg","datePublished":"2026-03-18T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260318418361\/pt\/2463563\/4\/Samsung_Bioepis_Songdo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260318418361\/pt\/2463563\/4\/Samsung_Bioepis_Songdo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/angelboss.com.br\/en\/2026\/03\/18\/328575-samsung-bioepis-firma-acordo-de-parceria-com-a-sandoz-para-ate-cinco-candidatos-a-biossimilares-de-ultima-geracao\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/angelboss.com.br\/"},{"@type":"ListItem","position":2,"name":"Samsung Bioepis firma acordo de parceria com a Sandoz para at\u00e9 cinco candidatos a biossimilares de \u00faltima gera\u00e7\u00e3o"}]},{"@type":"WebSite","@id":"https:\/\/angelboss.com.br\/#website","url":"https:\/\/angelboss.com.br\/","name":"Portal Masculino de Moda, Beleza, Luxo e Business - Angel Boss","description":"O Maior Portal sobre Moda, Luxo, Beleza e Business Masculino do Brasil","publisher":{"@id":"https:\/\/angelboss.com.br\/#organization"},"alternateName":"Maior Portal e Blog de Beleza Masculina e Luxo","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/angelboss.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/angelboss.com.br\/#organization","name":"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss","url":"https:\/\/angelboss.com.br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/angelboss.com.br\/#\/schema\/logo\/image\/","url":"http:\/\/angelboss.com.br\/wp-content\/uploads\/2025\/12\/WhatsApp-Image-2025-12-11-at-12.54.26.jpeg","contentUrl":"http:\/\/angelboss.com.br\/wp-content\/uploads\/2025\/12\/WhatsApp-Image-2025-12-11-at-12.54.26.jpeg","width":1280,"height":1280,"caption":"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss"},"image":{"@id":"https:\/\/angelboss.com.br\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/angelboss.com.br\/#\/schema\/person\/b6676b8d991f97199ef2d5b8e5c2d8a5","name":"DINO","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g","caption":"DINO"},"url":"https:\/\/angelboss.com.br\/en\/author\/DINO\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/posts\/15589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/comments?post=15589"}],"version-history":[{"count":0,"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/posts\/15589\/revisions"}],"wp:attachment":[{"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/media?parent=15589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/categories?post=15589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/tags?post=15589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}